NCT03761758View on ClinicalTrials.gov

Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Myopia
Interventions
DEVICE

Spectacle lenses

Spectacle lenses with clear central apertures

Trial Locations (1)

N2L 3G1

Centre for Ocular Research & Education, Waterloo

All Listed Sponsors
lead

SightGlass Vision, Inc.

INDUSTRY

NCT03761758 - Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast | Biotech Hunter | Biotech Hunter